Zacks Investment Research upgraded shares of Electromed, Inc. (NYSEMKT:ELMD) from a sell rating to a hold rating in a research report report published on Thursday morning.
According to Zacks, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest® Airway Clearance System and related products. The patented system uses High Frequency Chest Wall Oscillation (HFCWO), an alternative to Chest Physiotherapy (CPT), to deliver airway clearance treatment. The Company manufactures its products for use by chronically-ill patients who face health risks due to pneumonia and mucus accumulation in the lungs, particularly patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and neuro-muscular disorders. The purpose of its primary product, the SmartVest System, is to loosen, mobilize, and release respiratory secretions from the lungs. The Company’s products are primarily used in the home health care market and in hospitals. Electromed, Inc. is headquartered in New Prague, Minnesota. “
Separately, TheStreet upgraded Electromed from a hold rating to a buy rating in a report on Friday, September 16th.
Shares of Electromed (NYSEMKT:ELMD) opened at 4.21 on Thursday. The stock’s 50 day moving average price is $4.25 and its 200 day moving average price is $4.36. The company has a market capitalization of $34.59 million, a P/E ratio of 16.91 and a beta of 0.89. Electromed has a 52-week low of $1.55 and a 52-week high of $6.26.
Electromed (NYSEMKT:ELMD) last issued its quarterly earnings results on Tuesday, November 8th. The company reported $0.02 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by $0.01. The company earned $5.50 million during the quarter, compared to analysts’ expectations of $5.90 million. On average, equities research analysts forecast that Electromed will post $0.13 earnings per share for the current fiscal year.
In other Electromed news, Director William Eckles purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, November 10th. The shares were acquired at an average price of $3.61 per share, with a total value of $72,200.00. Following the purchase, the director now directly owns 13,072 shares in the company, valued at approximately $47,189.92. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Several institutional investors have recently made changes to their positions in the stock. Alambic Investment Management L.P. raised its position in shares of Electromed by 28.0% in the second quarter. Alambic Investment Management L.P. now owns 29,571 shares of the company’s stock valued at $114,000 after buying an additional 6,474 shares during the period. Eagle Global Advisors LLC purchased a new position in Electromed during the second quarter valued at about $134,000. Creative Planning raised its position in Electromed by 3.0% in the third quarter. Creative Planning now owns 34,000 shares of the company’s stock valued at $156,000 after buying an additional 1,000 shares during the last quarter. Acrospire Investment Management LLC raised its position in Electromed by 32.4% in the second quarter. Acrospire Investment Management LLC now owns 43,009 shares of the company’s stock valued at $166,000 after buying an additional 10,527 shares during the last quarter. Finally, Barclays PLC raised its position in Electromed by 66.4% in the second quarter. Barclays PLC now owns 48,600 shares of the company’s stock valued at $187,000 after buying an additional 19,400 shares during the last quarter.